Akira Yamauchi,
A topic at the meeting: An anti-PD-1 antibody, Nivolumab was approved in July 2014 in Japan for treatment of cancer. Now…
A topic at the meeting: An anti-PD-1 antibody, Nivolumab was approved in July 2014 in Japan for treatment of cancer. Now…
Combinatia tratamentelor imunologice Nivolumab (opdivo) si Ipilimumab (yervoy) in melanoma arata rezultate promitatoare in…
CHICAGO--The major excitement at ASCO last week was about "anti-PD1 therapy." PD-1 is "programmed death 1 receptor." Think of…
CHICAGO--The major excitement at ASCO last week was about "anti-PD1 therapy." PD-1 is "programmed death 1 receptor." Think of…